Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …

Background Monoclonal antibodies that target amyloid-beta (Aβ) have the potential to slow
cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is …

Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of
Alzheimer's disease (AD). Aβ exists as various species, including monomers, oligomers …

Importance The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab
provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that …

Abstract Background Lecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially
targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils, and …

Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …

Dominantly inherited Alzheimer's disease (DIAD) causes predictable biological changes
decades before the onset of clinical symptoms, enabling testing of interventions in the …